Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics IncfiledCriticalAmicus Therapeutics Inc
Publication of AR124827A1publicationCriticalpatent/AR124827A1/es
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente divulgación se refiere al suministro por virus adeno-asociado recombinante (rAAV) de un polinucleótido de lipofuscinosis neuronal ceroidea 3 (CLN3). La divulgación provee rAAV y métodos para usar el rAAV para la terapia génica de CLN3 de la lipofuscinosis neuronal ceroidea o la enfermedad de CLN3-Batten.
ARP220100241A2021-02-052022-02-07Suministro por virus adeno-asociado de polinucleótido cln3
AR124827A1
(es)
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
Electroacupuncture alleviates nerve injury after cerebra ischemia in rats through inhibiting cell apoptosis and changing the balance of MMP-9/TIMP-1 expression
Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth